Title page

Metabolism and Disposition of [14C]Pevonedistat, a First-In-Class NEDD8-Activating Enzyme Inhibitor, After Intravenous Infusion to Patients With Advanced Solid Tumors

Jayaprakasam Bolleddula[1], Hao Chen, Lawrence Cohen, Xiaofei Zhou, Sandeepraj Pusalkar[2],

Allison Berger, Farhad Sedarati, Karthik Venkatakrishnan[1], and Swapan K. Chowdhury[3]

Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

Current address:

[1]EMD Serono Research & Development Institute, Inc., Billerica, MA 01821

[2]Servier Pharmaceuticals, Boston, MA 02210

[3]Boston Pharmaceuticals, 55 Cambridge Parkway, Suite 400, Cambridge, MA 02142

1

Running Title Page

Running Title: Metabolism of pevonedistat in patients with cancer

Corresponding Authors:

Co-Corresponding Author Name: Swapan K. Chowdhury, PhD

Address: Boston Pharmaceuticals, 55 Cambridge Parkway, Suite 400, Cambridge, MA 02142

E-mail address: swapan@bostonpharmaceuticals.com

Co-Corresponding Author Name: Jayaprakasam Bolleddula, PhD

E-mail Address: bolleddulajp@yahoo.com

Keywords: Pevonedistat, NAE inhibitor, human ADME, metabolism, clearance mechanisms, accelerator mass spectrometry (AMS), reaction phenotyping, CYP3A4/5

Text pages: 21

Table count: 5

Figure count: 2

Reference count: 34

Abstract: 242

Introduction: 550

Discussion: 1389

Nonstandard Abbreviations: β-RAM, beta-particle emission radioactivity monitor; ACN, acetonitrile; AML, acute myeloid leukemia; AMS, accelerator mass spectrometer; AUC, area under the curve; C_{avg}, average concentration; CE, collision energy; CL, clearance ; CLint,rCYP, intrinsic clearance in recombinant CYP; CMML, chronic myelomonocytic leukemia; cpm, counts per minute; CRL, cullin-RING ligase; C_t, last quantifiable drug concentration; CYP, cytochrome P450; CYP_i, CYP of interest; DLBCL, diffuse large B-cell lymphoma; DDI, drug-drug interaction; HLM, human liver microsomes; HPLC, high-performance liquid chromatography; IV, intravenous; LC, liquid chromatography; LC/MS/MS, liquid chromatography with tandem mass spectrometry; MDS, myelodysplastic syndromes; MS, mass spectrometry; MS/MS, tandem mass spectrometry; MRM, multiple reaction monitoring; NAE, NEDD8-activating enzyme; NEDD8, neural precursor cell-expressed, developmentally downregulated gene 8; NF-κB, nuclear factor-kappa B; pMC, percent Modern Carbon; RAF, relative activity factor; rCYP, recombinant cytochrome P450; $t_{1/2}$, half-life; Tmax, time to peak concentration; TRA, total radioactivity; UPS, ubiquitin-proteasome system.

Abstract

Metabolism and disposition of pevonedistat, an investigational, first-in-class inhibitor of the NEDD8-activating enzyme (NAE), were characterized in patients with advanced solid tumors after intravenous infusion of [^{14}C]pevonedistat at 25 mg/m^2 (~60–85μCi radioactive dose). More than 94% of the administered dose was recovered, with ~41% and ~53% of drug-related material eliminated in urine and feces, respectively. The metabolite profiles of [^{14}C]pevonedistat were established in plasma using an accelerator mass spectrometer (AMS) and excreta with traditional radiometric analysis. In plasma, unchanged parent drug accounted for approximately 49% of the total drug-related material. Metabolites M1 and M2 were major (>10% of the total drug-related material) circulating metabolites and accounted for approximately 15% and 22% of the drug related material, respectively. Unchanged [^{14}C]pevonedistat accounted for approximately 4% and 17% of the dose in urine and feces, respectively. Oxidative metabolites M1, M2, and M3 appeared as the most abundant drug-related components in the excreta and represented approximately 27%, 26%, and 15% of the administered dose, respectively. Based on the unbound plasma exposure in cancer patients and in vitro NAE inhibition, the contribution of metabolites M1 and M2 to overall in vivo pharmacological activity is anticipated to be minimal. The exposure to these metabolites was higher at safe and well tolerated doses in rat and dog (the two preclinical species used in toxicology evaluation) plasma than that observed in human plasma. Reaction phenotyping studies revealed that CYP3A4/5 are primary enzymes responsible for the metabolic clearance of pevonedistat.

Significance Statement

This study details the metabolism and clearance mechanisms of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, after intravenous administration to patients with cancer. Pevonedistat is biotransformed to 2 major circulating metabolites with higher exposure in non-clinical toxicological species than in humans. The pharmacological activity contribution of these metabolites is minimal compared to the overall target pharmacological effect of pevonedistat. Renal clearance was not an important route of excretion of unchanged pevonedistat (~4% of the dose).

Introduction

The ubiquitin-proteasome system (UPS) regulates normal cellular functions such as cell cycle, signal transduction, cell death, immune responses, and metabolism, through intracellular protein degradation. This proteolytic process is catalyzed by a set of enzymes, ubiquitin-activating (E1) and ubiquitin-conjugating (E2) enzymes, and ubiquitin ligases (E3) (Hershko and Ciechanover, 1998). These enzymes link chains of the polypeptide cofactor, Ub, onto proteins to mark them for degradation by the 26S proteasome (multi-catalytic protease). Cullin-RING ligases (CRLs) are the largest family of ubiquitin E3 ligases that control turnover of many key substrates involved in cell cycle control, nuclear factor (NF)-κB signaling, and DNA replication and repair (Zhao and Sun, 2013). CRLs are activated by covalent binding of ubiquitin-like protein NEDD8 (neural precursor cell-expressed, developmentally downregulated gene 8) to their cullin subunits through neddylation, which requires the E1 NEDD-activating enzyme (NAE), as well as NEDD8-specific E2 and E3 enzymes. Deregulation of CRLs is linked to uncontrolled proliferative diseases such as cancer (Soucy et al., 2010). Thus, the NAE controls an early step in neddylation and represents a potential therapeutic target to modulate CRL activity and protein homeostasis (Zhao et al., 2014).

Pevonedistat [(((1*S*,2*S*,4*R*)-4-{4-[(1*S*)-2,3-dihydro-1*H*-inden-1-ylamino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate hydrochloride; MLN4924; TAK-924) is a first-in-class, small-molecule, potent, and selective inhibitor of the NAE and is currently in clinical development across multiple cancers (Swords et al., 2018). Pevonedistat effectively blocks cullin neddylation to inhibit the activation of CRLs, leading to CRL substrate accumulation and the subsequent induction of multiple cell death pathways in cancer cells (Soucy et al., 2009). In xenograft models of diffuse large B-cell lymphoma (DLBCL) (OCI-Ly10

6

and OCI-Ly19) and acute myeloid leukemia (AML) (HL-60), pevonedistat demonstrated a dose-dependent decrease in neddylated-cullins and a dose-dependent increase in CDL substrate pIκBα (phosphorylated protein inhibitor of nuclear [transcription] factor-κB) (Milhollen et al., 2010; Swords et al., 2010). Pevonedistat has been evaluated as a monotherapy in patients with a variety of advanced malignancies including solid tumors (Sarantopoulos, 2016), relapsed or refractory lymphoma and multiple myeloma (Shah 2016), and AML (Swords et al., 2015). It has also been evaluated in combination with azacitidine in AML (Swords et al., 2018) and with several chemotherapy regimens in patients with advanced solid tumors, including docetaxel and carboplatin plus paclitaxel (Lockhart et al., 2019). A phase 2 trial of pevonedistat combination therapy with azacitidine in patients with higher-risk myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), and low-blast AML demonstrated encouraging clinical activity (NCT03814005) (Sekeres et al., 2021).

Pevonedistat was biotransformed via oxidative metabolism as a major clearance pathway in vitro and in preclinical species (rat and dog) (unpublished data). Metabolism and excretion studies in humans are routinely performed with radiolabeled investigational drug to determine circulating levels of a drug and its metabolites, to determine excretory metabolic pathways and to elucidate the clearance mechanism of a drug (Penner et al., 2009; Coppola et al., 2019). Hence, an open-label phase 1 trial was conducted to evaluate the mass balance, metabolism, routes of elimination, and pharmacokinetics of [14C]pevonedistat following intravenous (IV) infusion to patients with advanced solid tumors (NCT03057366). The mass balance, pharmacokinetics, and excretion of [14C]pevonedistat have been reported recently (Zhou et al., 2021a). This article presents the characterization of circulating/excretory human metabolites and pharmacological

7

activity of major circulating metabolites and assesses exposure coverage in preclinical toxicological species along with metabolic enzymes involved in the clearance of pevonedistat.

Materials and Methods

Test Articles and Reagents

[^{14}C]Pevonedistat hydrochloride was synthesized at Quotient Sciences (Reading, UK). The radiochemical purity was ≥99% with high-performance liquid chromatography (HPLC) purity of 100%. The metabolite standard references M1 (ML00756900-001-C), M2 (ML00756899-001-B), and M3 (ML00756898-001-C) were synthesized at Millennium Pharmaceuticals, Inc. (Cambridge, MA, USA), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, with purity >98%. Ammonium acetate and acetic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA) and J. T. Baker (Phillipsburg, NJ, USA), respectively. Liquid scintillation cocktail Ultima Gold and liquid cocktail Microscint-PS for microplates (Isoplate-96) were obtained from PerkinElmer (Waltham, MA, USA). The liquid scintillator FlowLogic U for beta-particle emission radioactivity monitor (β-RAM) was purchased from LabLogic (Brandon FL, USA). The human cDNA-expressed recombinant cytochrome P450s (rCYPs) were purchased from Corning (Woburn, MA, USA). Human liver S9 fractions (HS9) (mixed gender pool of 200 donors) were purchased from Sekisui-Xenotech (Lenexa, KS, USA). Acetonitrile (ACN), methanol, water, and all other reagents in high grade were purchased from commercial vendors.

Clinical Study Design and Dosing

Detailed clinical design, mass balance, and pharmacokinetics have been published recently (Zhou et al., 2021a). Briefly, the study was a single-center, open-label, nonrandomized study with two parts: Part A to evaluate the mass balance, metabolism, and excretion of

8

pevonedistat following an intravenous infusion in patients with cancer, and part B (optional) was continued treatment with pevonedistat (20 mg/m^2; Days 1, 3, 5) in combination with chemotherapeutic agents (either docetaxel or carboplatin plus paclitaxel). This study was conducted in compliance with the independent ethics committee requirements of the participating region, informed consent regulations, and applicable regulatory requirements (including International Council for Harmonization guidelines), in accordance with ethical principles founded in the Declaration of Helsinki. The sterile liquid formulation (1 mg/mL) of pevonedistat was a solution containing citric acid (anhydrous) and beta cyclodextrin sulfobutyl ethers (Captisol®), trisodium citrate dehydrate, and dextrose. [^{14}C]Pevonedistat at 25 mg/m^2 (approximately 80 μCi) was administered intravenously (60 min) to 8 cancer patients with advanced solid tumors. The objective of this part of the study was to profile and identify circulating and excretory metabolites of pevonedistat. Blood samples were collected for measurement of total radioactivity (blood and plasma), pevonedistat concentration, and metabolite profiling at pre-dose, end-of-infusion, and 0.5, 1, 2, 3, 4, 8, 12, 24, 48, 72, and every 24 hours thereafter until the release criteria were met. Urine samples (total radioactivity, pevonedistat, and metabolite profiling) were collected from 24 hours prior to dosing and at 0 to 6, 6 to 12, 12 to 24, and every 24 hours post-dose until patients were released. Feces were collected at pre-dose and at 24-hour intervals after dosing until release criteria were met and homogenized in water.

Sample Preparation for Metabolite Profiling

Plasma samples were pooled according to the Hamilton method across time points (0 to 72 hours) to create a single area under the curve (AUC)-representative pooled sample per patient (Hamilton et al., 1981). The pooling time points comprised >4t$_{1/2}$ of the total radioactivity

in plasma. Pooled plasma (500 µL) samples were protein-precipitated with 3 volumes of acetonitrile; vortex-mixed for 5 minutes and stored at 4°C for 30 minutes; and centrifuged. Supernatant was transferred and reduced to partial dryness under a stream of nitrogen, at 40°C until approximately 200 µL remained in the centrifuge tube. The concentrated extract was diluted with mobile phases A [10mM ammonium acetate (pH 5.6)] and mobile phases B [ACN/methanol (1:1 [v/v])], and recoveries (extraction and reconstitution) were assessed. Human urine and fecal homogenate samples were pooled by combining a constant percentage of volume/weight excreted during each collection interval and creating a single pooled sample per individual subject. The pooled time points were selected to achieve a minimum of ≥86% of the excreted radioactivity in urine or feces. Pooled urine samples were centrifuged, dried down under vacuum, and reconstituted with mobile phases A and B (1:1, v/v). Aliquots of pooled fecal homogenate samples were extracted 3 times with 3 volumes of ACN/methanol (1:1 [v/v]), and supernatants were separated. The combined extracts were dried under vacuum and reconstituted with mobile phases A and B (1:1, v/v). The extraction, reconstitution, and column recovery were assessed for individual subjects. Metabolite profiling of urine and fecal homogenate extracts was performed using conventional HPLC. Radioactivity detection was performed using a β-RAM radioactivity detector, while that of plasma extracts was performed using HPLC fractionation and accelerator mass spectrometer (AMS).

HPLC Conditions and Excreta Profiling

The chromatographic separations were achieved on a Phenomenex Luna® C18 (2) column (250 × 4.6 mm, 5 µm, 100Å) (Phenomenex, Inc. [Torrance, CA, USA]) with a Phenomenex guard column cartridge (Phenomenex, Inc.) at 40°C on an Agilent 1290 Infinity HPLC system (Agilent Technologies [Wilmington, DE, USA]). Mobile Phases A and B were

10-mM ammonium acetate (pH 5.6) and ACN/methanol (1:1 [v/v]), respectively. The flow rate was 0.7 mL/min with a linear gradient from 5%B to 10%B in 5 minutes, followed by a ramp to 40%B in 20 minutes. It then went to 30%B in 30 minutes; back to 40%B in 35 minutes; to 60%B in 40 minutes; a ramp to 100%B until 50 minutes with hold up to 55 minutes; and back to 5%B at 60 minutes. The ultraviolet (UV) detector was set at 276 nm. A 500-μL liquid cell (LabLogic System Inc. [Brandon, FL, USA]) was used for the β-RAM radiometric detector, and the flow rate of liquid scintillator FlowLogic U (LabLogic System Inc.) was 1.5 mL/min. For urine samples, HPLC elutes were collected in OptiPlate-96 (white opaque 96-well microplate) by the fraction collector, dried, and counted for 5 to 10 minutes by microplate counter (MicroBeta2, Perkin Elmer) by mixing with scintillation cocktail. The system operation was controlled by Laura software, Version 4.2.4.50 (LabLogic System Inc.). The radiochromatograms were integrated by Laura to obtain the percent distributions for the metabolites as shown by the radio-peaks. Fecal metabolite profiles were generated using the online radioactivity detector, β-RAM model 5C (LabLogic System Inc.).

Plasma Metabolite Profiling with AMS

The $t_{1/2}$ of plasma total radioactivity is approximately 15 hours; hence, plasma was pooled up to 72 hours to reflect 4 to 5 half-lives of total radioactivity. Due to pooling of plasma up to 72 hours, the radioactivity concentration in the pooled sample was deemed insufficient for detection by traditional radioactivity detection methods (eg, using β-RAM); thus, AMS was used for plasma metabolite profiling. The HPLC analysis was performed using the method described in the previous section, and eluants were collected as a series of fractions every 15 seconds. An equal proportion of volume from each individual fraction was pooled for AMS analysis. The pooled samples were dried under vacuum in the presence of copper oxide and placed into a combustion tube, which was heat-

11

sealed under vacuum and heated at 900°C for 1 hour in a chamber furnace (Keck et al., 2010; Tse et al., 2014). The carbon dioxide generated by combustion was cryogenically transferred to a tube containing Zn powder and titanium hydride and graphitized by placing in a furnace and heating at 550°C for 5 hours. The graphite pellet was prepared from graphitized material and loaded on to the sample wheel, which was inserted into the ion source of the AMS instrument. The ion source (Multi Cathode-Source of Negative Ions by Cesium Sputtering created a beam of negative ions by directing the Cs on to the graphite sample and sputtering the surface. After sequential injection of $^{12}C^-$, $^{13}C^-$, and $^{14}C^-$ into the accelerator, the abundant $^{12}C^+$ and $^{13}C^+$ ions were collected in the off-axis faraday cups, and their respective currents were measured very precisely using a current integrator. The $^{14}C^+$ ions were selected based on their charge state using an electrostatic analyzer and counted using a silicon surface barrier detector. The AMS measured the $[^{14}C]:[^{12}C]$ ratio derived from all sources of carbon in the sample. The AMS results were expressed as percent Modern Carbon (pMC), where 100 pMC equals 13.56 dpm/g C, and plotted with Laura software; relative percentages were calculated. Regions of radioactivity were identified using a UV chromatogram of plasma extract spiked with unlabeled pevonedistat, M1, M2, and M3 reference standards. Metabolites, M7-, M10b-, M16-, and M22-related regions were identified based on the known retention times from urine sample analysis and mass spectrometry of plasma samples.

Metabolite Identification

Metabolites in urine, fecal homogenates, and plasma samples were identified using a Triple TOF™ 5600 high-resolution mass spectrometer (AB SCIEX [Framingham, MA, USA]) in positive ionization modes. The HPLC eluate was introduced via an electrospray positive ionization source directly into the mass spectrometer with the following conditions: collision energy (CE) = 45 ± 15 v; curtain gas = 30 (arbitrary units); declustering potential = 60; and

source temperature = 450°C. The mass defect tolerance was set at 50 with the parent's mass. The

data were acquired using Analyst® TF 1.7 software (AB SCIEX) and processed with Peakview®

2.1 software (AB SCIEX). Putative structures of metabolites were determined using elemental

composition derived from the accurate mass, change in elemental composition relative to the

parent drug, retention time when reference standards were available, and MS/MS fragmentation.

Cytochrome P450 Reaction Phenotyping of Pevonedistat

To determine the in vitro intrinsic clearance of pevonedistat in rCYPs, pevonedistat

(0.1 μM) was incubated with rCYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 2J2, 3A4,

and 3A5 (20 pmol/mL). The total protein concentration was adjusted to 0.5 mg/mL (except for

CYP1A1, 0.56 mg/mL) with appropriate control Supersomes™ showing no endogenous P450

activity (control Supersomes™ with either P450 oxidoreductase or with both P450

oxidoreductase and Cytochrome b$_5$). The incubations were conducted in triplicate in 0.1-M

potassium phosphate buffer supplemented with 2-mM nicotinamide adenine dinucleotide

phosphate (NADPH) and 3-mM MgCl$_2$, pH 7.4, at 37°C over 0, 3, 7, 12, 20, and 30 minutes. The

reactions were terminated by the addition of 0.1-μM d_8-pevonedisat (internal standard) in ACN.

A 50-μL aliquot of the supernatant was then further diluted with 100 μL of water prior to

analysis by liquid chromatography with tandem mass spectrometry (LC/MS/MS). To evaluate

the role of the CYP4F family in pevonedistat metabolism, pevonedistat (0.1-μM) was also

incubated with CYP4F2, 4F3A, 4F3B, and 4F12 as above, except for only 0- and 30-minute time

points. The disappearance of pevonedistat over time was monitored by LC/MS/MS. Relative

activity factor for each CYP-enzyme was established using CYP-specific probe substrate for

each CYP: 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5. Intrinsic clearance in recombinant

CYPs (CL$_{int,rCYP}$) was calculated for pevonedistat and extrapolated to human liver microsomal

13

(HLM) clearance for the CYP of interest using the relative activity factor approach (Venkatakrishnan et al., 2000; Venkatakrishnan et al., 2001). The relative contribution of each hepatic enzyme toward the metabolic clearance of pevonedistat was assessed.

Intrinsic CL of pevonedistat at 0.1 µM concentration was determined in human S9 fraction (2.5 mg/mL) in the presence of NADPH (30 min incubation) and with and without the CYP3A-specific inhibitor ketoconazole (0.5 µM). The % inhibition of the metabolism of pevonedistat by ketoconazole was assessed from this data.

Pharmacological Activity of Metabolites

In vitro pharmacological activity of pevonedistat and major circulating metabolites M1 and M2, and along with metabolite M3, was evaluated in: 1) a biochemical assay for NAE inhibition; 2) a cell-based NF-κB-luciferase reporter assay in HEK293 cells in which the luciferase signal requires NAE-dependent ubiquitination of the NF-κB inhibitor IκBα; and 3) a tumor cell viability assay in HCT116 cells as per published procedure (Soucy et al., 2009).

Metabolite Profiling of Rat and Dog Plasma

Male Sprague-Dawley rats were administered 30 mg (100 µCi)/kg of [^{14}C]pevonedistat. 30 mg/kg was a safe and tolerable dose in toxicology studies in the rat. Terminal blood samples from rats were collected at 0.25, 0.5, 0.583, 0.833, 1.5, 3.5, 6.5, 8.5, 12.5, 24.5, 48.5, 72.5, 96.5, 120.5, 144.5, and 168.5 hours from the start of infusion (3 rats/time point). Pre-dose and individual plasma samples were pooled across time points and animals using the trapezoidal AUC pooling method (Hamilton et al., 1981). The drug-derived radioactivity from pooled plasma was extracted twice from plasma samples using 2X v/v of acetonitrile. The metabolite profiles were established using HPLC fraction collection and detection of radioactivity by Packard TopCount NXT Microplate Scintillation and Luminescence Counter technology.

14

Three male beagle dogs received a single IV infusion (30 minutes) of $[^{14}C]$pevonedistat at 15 mg

(40 μCi)/kg. 15 mg/kg was a safe and tolerable dose in toxicology studies in the dog. Blood

samples were collected from all dogs prior to dosing and at approximately 0.5 (end of infusion),

0.75, 1, 3, 6, 8, 10, 24, 48, and 72 hours post-start of infusion. Pre-dose and individual plasma

samples were pooled across time points using the trapezoidal AUC pooling method. Aliquots of

pooled plasma samples were extracted with ACN (1:3 [v/v]) 3 times and processed for

metabolite profiling by HPLC/β-RAM or HPLC-fraction collector followed by a microplate

reader. All the procedures and protocols for in vivo animal studies were carried out in

accordance with the Guide for the Care and Use of Laboratory Animals as adopted and

promulgated by the U.S. National Institutes of Health, and were approved by the Institution's

Animal Care and use Committee or local equivalent.

Data Processing and Analysis

Metabolite profiles were generated by directly acquiring the data from β-RAM or

importing MicroBeta/AMS data using the liquid scintillation counting import function in Laura™

software (Lablogic, Brandon, FL). Percent distribution of pevonedistat and metabolites was

calculated by direct integration of the peak areas from metabolite profiles and converted to %

dose of metabolites.

The measured CL_{int} with individual CYPs was extrapolated to HLM clearance for the

CYP of interest (CYP_i) using the relative activity factor for CYP_i as shown in Equation 1.

Intrinsic clearance ($CL_{int,HLM, CYPi}$) = ($CL_{int,rCYP}$) (RAF_{CYPi}) (1)

Where: $CL_{int, HLM, CYPi}$ = intrinsic clearance in HLM by CYP_i (mL/min/mg protein); $CL_{int,}$

$_{rCYPi}$= intrinsic clearance by $rCYP_i$ (mL/min/pmol P450); RAF = relative activity factor,

determined using CYP-specific probe substrate = $CL_{int,HLM,CYPi}$ / $CL_{int,rCYPi}$ (pmol P450/mg protein).

The percent contribution of individual hepatic CYP was then determined using Equation 2.

Percent (%) Contribution of CYP_i = ($CL_{int,HLM, CYPi}$) / $\Sigma(CL_{int,HLM, CYP}$) (2)

Where: $\Sigma(CL_{int,HLM, CYP})$ = sum of intrinsic clearance by CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5.

Results

Excretion of Drug-related Material

Eight cancer patients with advanced solid tumors each received a 25-mg/m^2 (~60-85 µCi) single IV infusion of [^{14}C]pevonedistat for 60 minutes in part A of the study (Zhou et al., 2021a). Although metabolite profiling was performed for all 8 patients who completed part A of the study, the results of 1 patient were excluded in the final summary due to use of CYP-3A-inducing medication (carbamazepine) that was included in the protocol's exclusion list. The mean recovery of radioactivity in urine and feces combined was approximately 94% by 1 week post-intravenous administration of [^{14}C]pevonedistat. Most of the radioactivity was recovered by 96 hours post-dose. A mean of ~53% and 41% of the dose was recovered in feces and urine, respectively (Zhou et al., 2021a). The mean $t_{1/2}$ of pevonedistat and drug-related material (total radioactivity) in plasma was 8.4 hours and 15.6 hours, respectively. The unchanged parent accounted for approximately 41% of AUC_{last} of total radioactivity, suggesting that 59% of the circulating radioactivity was due to metabolites (Zhou et al., 2021a).

Metabolite Profiles in Plasma

Metabolite profiles of AUC-pooled plasma (0 to 72 hours) for individual subjects were established using HPLC fractionation followed by AMS analysis. The mean samples processing

(extraction and reconstitution) and column recoveries were determined as 90 and 106%,

respectively.   Percent distribution of pevonedistat and its metabolites in plasma are summarized

in Table 1, and the structure of metabolites are presented in Figure 1. The reconstructed HPLC

radio-chromatograms showed the presence of 6 circulating metabolites (Figure 2a). The most

abundant radio-peak was due to unchanged pevonedistat contributing to approximately 49% of

the total circulating radioactivity. This is close to the ratio (~41%) obtained from the AUC of the

parent drug from direct measurement of the parent drug concentration using a validated

bioanalytical method and to that of the total radioactivity calculated from the time-concentration

profile. Hydroxylated metabolites M1 and, further oxidized to a ketone metabolite, M2, appeared

as the major (>10% of the total radioactivity) metabolites in plasma; these represented

approximately 15% and 22% of the total radioactivity, respectively (Table 1). Metabolites M3

(hydroxylation) and M10b (oxidation and glucuronidation) accounted for approximately 5% and

7% of the total radioactivity, respectively. Metabolites M7 (N-dealkylation), M16 (direct

glucuronidation), and M22 (oxidation and glucuronidation) were relatively minor metabolites,

and each represented ≤2% of the total radioactivity (Table 1). The structure of minor metabolite,

M23 could not be identified.

Metabolite Profiles in Excreta

The percentage of the dose excreted as pevonedistat and metabolites are summarized in

Table 1. The mean samples processing (urine: 102%; feces: 97%) and column (urine: 104%;

feces: 98%) recoveries were >95%. Metabolite profiles of pooled urine samples revealed the

presence of up to 9 metabolites (Figure 2b). Approximately 41% of the administered dose was

excreted in urine. Unchanged pevonedistat accounted for approximately 4% of the administered

dose in urine. M1 was the major metabolite, which represented approximately 20% of the

17

administered dose. Metabolites M2, M3, and M16 represented approximately 8%, 4%, and 3% of the dose, respectively. M7, M10b, and M22 are minor metabolites, and each accounted for <2% of the administered dose. Approximately 53% of the administered dose was excreted in feces. Unchanged pevonedistat accounted for approximately 17% of the dose (Figure 2c; Table 1). M1, M2, and M3 were major metabolites that accounted for approximately 7%, 18%, and 11% of the dose, respectively. Metabolite M7 was a minor metabolite and accounted for <1% of the dose.

Overall, ~74% of the dose was excreted as metabolites in urine and feces, combined with 21% (4% and 17% of the dose in urine and feces, respectively) as parent drug.

Identification of Metabolites

The structures of the metabolites were characterized by measuring the change in both elemental composition and characteristic fragment ions and their accurate *m/z* compared to that of pevonedistat (Figure 1; Table 2). The biotransformation of pevonedistat to metabolites M1, M2, and M3 resulted from hydroxylation (M1 and M3, +16 Da) and subsequent oxidation to a ketone (M2, +14 Da). Additionally, the identities of metabolites M1, M2, and M3 were confirmed by comparison with the retention time of the corresponding reference standards (Table 2).

CYP Reaction Phenotyping

The metabolite profiling data from this study confirmed that pevonedistat was primarily cleared via metabolism, with oxidation being the predominant pathway. Metabolites M1, M2, and M3 accounted for approximately 68% of the total dose excreted in urine and feces combined (Table 1). All oxidative pathways combined represented ~72% of the administered dose. To determine the enzymes responsible for pevonedistat metabolism, the clearance of pevonedistat was measured in the presence of rCYPs: CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1,

2J2, 3A4, 3A5, 4F2, 4F3A, 4F3B, and 4F12. Only CYP3A4/5, 2C8, 2J2, and 1A1 were shown to meaningfully contribute to the pevonedistat metabolism with $CL_{int,rCYP}$ 3.27E-03, 1.04E-04, 7.01E-04, and 7.01E-04 mL/min/pmol P450, respectively (Table 3). Since CYP1A1 and 2J2 are primarily extra-hepatic enzymes with low expression in the liver, the quantitative contribution of these CYPs could not be assessed. The quantitative contribution of CYPs in the clearance of pevonedistat was assessed for the following hepatic CYPs only: CYP1A2, 2B6, 2C8, 2C9, 2D6, and 3A4/5- using the RAF. Among hepatic CYPs, CYP3A4/5 contributed approximately 94% to the overall hepatic metabolism, and CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 contributed <2% each (Table 3).

Pharmacological Activity of Metabolites

In vitro pharmacological activity of pevonedistat and its oxidative metabolites (M1, M2, and M3) was assessed in biochemical, reporter, and cell viability assays; the results are summarized in Table 4. Pevonedistat and its oxidative metabolites—M1, M2, and M3— exhibited similar 50% inhibitory concentration (IC_{50}) values (0.004~0.010) compared to pevonedistat (within 2-fold range) in an NAE inhibition biochemical assay. However, in the cell-based NF-κB inhibition assay (the most relevant assay for target pharmacological activity), M1, M2, and M3 were 8- to 13-fold less potent than pevonedistat (IC_{50} [μM]): pevonedistat: 0.016; M1: 0.13; M2: 0.13; M3: 0.20, and in the HCT116 viability assay (dose causing lethality for 50% of the population [LD_{50}] [μM]: pevonedistat: 0.12; M1: 0.41; M2: 0.43; M3: 0.99), the metabolites were also less potent, in the 3- to 8-fold range (Table 4). Based on the plasma exposure, unbound fraction in plasma, and NF-κB inhibition IC_{50}, the contribution of metabolites to the overall pharmacology of pevonedistat is expected to be minor.

Cross-Species Comparison of Metabolites

The excretion, mass balance, and metabolism of pevonedistat was also evaluated following IV administration of ^{14}C-pevonedistat in rats and dogs, the 2 species used in the toxicology assessment for pevonedistat (data on file). In general, the exposure to the circulating metabolites in toxicological species at doses that were safe and well tolerated, are broadly similar to or higher than that observed in humans. There were no human-specific circulating metabolites identified in this study. A quantitative comparison of the 2 major metabolites (>10% of total radioactivity in human plasma), M1 and M2, in rats, dogs, and humans is presented in Table 5. M1 and M2 represented approximately 15% and 22% of the drug-related material in human plasma, which is equivalent to 545 and 802 hr*ng*Eq/mL, respectively. Both metabolites M1 and M2 were present at approximately 1~4-fold and 2~6-fold higher exposure in rat and dog plasma, respectively.

Discussion

Pevonedistat is a first-in-class inhibitor of the NAE and is currently in clinical development across multiple cancers, including low-blast AML and high risk MDS (NCT03814005). A human metabolism and excretion study with [^{14}C]pevonedistat was conducted to understand the mass balance and routes of elimination and to elucidate clearance mechanisms of pevonedistat in patients with advanced cancer (Zhou et al., 2021a). The quantitative information on circulating and excretory metabolites obtained from the ADME study is critical to understand the potential for drug-drug interactions (DDIs) as a victim and the contribution of metabolites to the pharmacology/toxicology of a parent drug. In addition, information on the level of circulating metabolites is important to assess DDI potential for metabolites as perpetrators. The mean total recovery in urine and feces was greater than 90% of the administered radioactivity. Most of the dose was excreted within 4 days of pevonedistat

administration, and excretion was essentially complete in 1 week. The excretion profiles were

similar across subjects with low inter-subject variability. Total drug-related material in plasma

declined at a slightly slower rate than pevonedistat, suggesting that some metabolites have longer

half-lives than the parent drug (Zhou et al., 2021a).

If designed and conducted appropriately, the radiolabeled human metabolism and

disposition study is one of the key clinical pharmacology studies that can provide a rich source of

information related to absorption, metabolism, and excretion of a new chemical entity (Penner et

al., 2009; Spracklin et al., 2020; Yeo and Venkatakrishnan, 2020). Recently, Coppola and Cole

reviewed the marketing authorization applications submitted during last 10 years to the European

Regulatory Agency (EMA) and highlighted many shortcomings related to the characterization of

circulating and excretory metabolites from human ADME studies (Coppala et al., 2019).

Despite extensive literature and guidance, inadequate sample pooling and

characterization of circulating metabolites in plasma were observed in many cases. In the current

study, for metabolite profiling, plasma samples were pooled for up to 72 hours using the AUC

pooling method to capture approximately 4 to 5 half-lives of drug-related material (Hamilton et

al., 1981). Due to pooling of up to 72 hours, plasma radioactivity was diluted, and metabolite

profiling could not be performed using traditional radioactivity detection methods. This is one of

the limitations of AUC pooling methods; accordingly, an ultra-highly sensitive AMS method

was utilized to detect low amounts of radioactivity in the metabolite profiles of the plasma pools.

The unchanged pevonedistat is the most abundant (~49%) radioactivity-related peak (Table 1

and Figure 2a) in plasma. This is close to the AUC_{last} ratio (~41%) for pevonedistat to total

radioactivity measured with the validated LC/MS/MS method. The minor difference in

pevonedistat levels may be due to differences in time intervals assessed (48 hours vs 72 hours)

21

and/or differences in sensitivity and/or extraction efficiencies between AMS and LC/MS/MS methods. M1 and M2 each represented >10% of the total circulating drug-related material. Other metabolites—M3, M10b, M7, M16, and M22—were minor, as each represented <10% of total radioactivity.

Pevonedistat was primarily metabolized via hydroxylation and oxidation. M1 and M3 are hydroxylated metabolites (epimeric) that accounted for ~27% and ~15% of the administered dose, respectively, excreted in urine and feces combined. M2 is the result of further oxidation of M1 and/or M3 and accounted for 27% of the administered dose. After IV administration, ~4% and ~17% of the dose was recovered as unchanged parent drug in urine and feces, respectively. The unchanged parent drug in feces may have resulted from either biliary excretion or intestinal secretion after IV administration, although according to preclinical studies, intestinal secretion does not appear to be a contributor (unpublished results). M1 and M3 are epimeric metabolites and their formation is primarily catalyzed by CYP3A4/5 enzymes. Metabolite, M2 could be formed by CYP enzymes and/or alcohol dehydrogenases mediated oxidation of M1 and M3 and this process is documented in the literature (Di et al., 2021; Diao et al., 2013). Conversely, M2 could also be converted back to M1 and M3 by aldo-keto reductases and/or the short-chain dehydrogenases/reductases (e.g carbonyl reductase) (Barski et al., 2008; Shi and Di, 2017). However, the mechanism and enzymes associated with the formation of M2 and its reduction back to M1 and M3 was not determined in this study but may be a subject of future investigations. The excretion of a very low level of unchanged pevonedistat in urine suggested that the renal clearance was not an important route of excretion of pevonedistat after IV administration.

The human metabolism and excretion study and the CYP phenotyping study revealed that oxidative metabolism was the predominant metabolic pathway of pevonedistat and was primarily catalyzed by CYP3A4/5 (approximately 94% contribution). In liver microsomes, 88% of

22

intrinsic clearance of pevonedistat was inhibited by ketoconazole (0.5 μM), a CYP3A4/5 inhibitor, consistent with the data from reaction phenotyping experiments with rCYPs. The metabolite profiling data from human excreta indicated that at least 74% of the administered dose was cleared via oxidative metabolism. Thus, the data from in vitro experiments are consistent with data observed in vivo in the human metabolism and excretion study. Although CYP3A4/5 were the primary enzymes responsible for the metabolic clearance of pevonedistat, a clinical DDI study with a strong CYP3A4/P-gp inhibitor, itraconazole, did not show any meaningful increase in pevonedistat systemic exposure (Faessel et al., 2019). Hepatic uptake parameters were assessed in sandwich-cultured hepatocytes (unpublished results). Development of a physiologically based pharmacokinetic model by incorporation of hepatic uptake parameters (CL_{PD}, *Jmax*, K_m) indicated that the systemic exposure of the drug is not sensitive to the perturbations of hepatic enzyme activity in the liver when the hepatic uptake becomes the rate-determining step of drug clearance. The results of mechanistic investigations, including physiologically based pharmacokinetic modeling exploring the lack of DDI for pevonedistat with CYP3A4/P-gp inhibitors and inducers, have been recently presented (Zhou et al., 2021b). This phenomenon has been described for other drugs as reported in the literature (Maeda et al., 2011; Yoshikado et al., 2017, Patilea-Vrana and Unadkat, 2018).

NAE is an essential E1 enzyme that initiates a protein homeostatic pathway essential for cancer cell growth and survival through the activation of a family of E3 ubiquitin ligases known as CRLs. When NAE is functional, CRL substrates involved in processes including DNA replication, cell cycle regulation, and NF-κB signaling are ubiquitinated and degraded in a regulated manner. In contrast, inhibition of NAE with pevonedistat results in accumulation of these CRL substrates and can lead to effects including DNA re-replication and inhibition of NF-

κB (Soucy, et al. 2010). The pharmacological activity of pevonedistat and metabolites M1–M3 was assessed in biochemical, reporter, and cell viability assays. Although pharmacological activity of the major circulating metabolites, M1 and M2, was similar to pevonedistat in a cell-free biochemical assay of NAE activity, when evaluated in cell-based assays, the activity of the metabolites was much weaker than that of pevonedistat. The shift in IC_{50} values (3- to 13-fold) from biochemical to pharmacologically more relevant cellular assays is likely due to differences in cellular permeability between pevonedistat and the metabolites. By including relative concentration, the plasma unbound fraction, and differences in cellular potency (NF-κB inhibition) of pevonedistat and metabolites, the contributions of metabolites to overall pharmacology activity were found to be minimal and are not expected to be clinically relevant.

Following the administration of pevonedistat, metabolites M1 and M2 exceeded the 10% threshold of circulating metabolites as described in FDA Safety Testing for Drug Metabolites guidance and ICH M3 (R2) documents (US Department of Health and Human Services, 2020; European Medicines Agency, 2008). The exposure of these two metabolites was assessed in the rat and dog ADME studies at doses that were safe and well tolerated (Table 5). Both M1 and M2 were major circulating metabolites in rats and dogs and were present at approximately 1~6-fold higher concentration in animals relative to that in humans, suggesting adequate animal exposure was achieved in the toxicological species in safety assessment studies.

In summary, the biotransformation and clearance pathways of pevonedistat were characterized after IV infusion of 25 mg/m^2 to patients with cancer. The mass balance results confirmed that drug-related material was excreted via both hepatic and renal elimination routes. However, renal elimination of unchanged pevonedistat was minor. Approximately 74% of the administered dose was recovered as oxidative metabolites in the excreta. The contribution of

24

major circulating metabolites M1 and M2 to overall pharmacological activity of pevonedistat is

minimal.

Acknowledgements

Authorship contributions

Participated in research design: Bolleddula, Chen, Zhou, Cohen, Pusalkar, Sedarati,

Venkatakrishnan, Chowdhury

Conducted experiments: Chen, Cohen

Performed data analysis: Bolleddula, Chen, Cohen, Pusalkar, Berger, Chowdhury

Wrote or contributed to writing of the manuscript: Bolleddula, Chowdhury

25

References

Barski OA, Tipparaju SM, Bhatnagar A (2008) The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification. Drug Metab Rev 40: 553–624.

Coppola P, Andersson A, Cole S (2019) The Importance of the Human Mass Balance Study in Regulatory Submissions. CPT Pharmacometrics Syst Pharmacol 8: 792-804.

Di L, Balesano A, Jordan S, Shi SM (2021) The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. AAPS J 23:20.

Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, Chen X (2013) Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos 41:430-444.

European Medicines Agency. Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. London, UK: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2008.

Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.

Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou V, Venkatakrishnan K, Harvey DR (2019) Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol 85: 1464-1473.

Keck BD, Ognibene T, Vogel JS (2010) Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2: 469-485.

26

Lockhart CA, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK,

Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A (2019) Phase Ib study of

pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel,

carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest

New Drugs 37: 87-97.

Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y,

Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance

of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Therap 90: 575-

581.

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey

JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy

TA, Yu J, Zhang J, Bolen JB, Smith PG (2010) MLN4924, a NEDD8-activating enzyme

inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of

NF-κB-dependent lymphoma. Blood 116: 1515-23.

Patilea-Vrana GI, Unadkat JD (2018) When Does the Rate-Determining Step in the Hepatic

Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances?

Implications for Predicting Drug-Drug Interactions. Drug Metab Dispos 46: 1487-1496.

Penner N, Klunk LJ, Prakash C (2009) Human radiolabeled mass balance studies: objectives,

utilities and limitations. Biopharm Drug Dispos 30:185-203.

Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam

D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD

(2016) Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat

(TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res 22:847-857.

Sekeres MA, Watts J, Radinoff A, Sangerman MA, Cerrano M, Lopez PF, Zeinder JF, Campelo MD, Graux C, Liesveld J, Sallesleg D, Tzvetkov N, Fram RJ, Zhao D, Bell J, Friedlander S, Faller DV, Ades L (2021) Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low blast AML. Leukemia 35:2119-24

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S (2016) Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res 22:34-43.

Shi SM, Di L (2017) The role of carbonyl reductase 1 in drug discovery and development. Expert Opin Drug Metab Toxicol 13:859-870.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke JE, Cardin JP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP (2009) An Inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736.

Soucy TA, Dick, LR, Smith, PG, Milhollen, MA, Brownwell, JE (2010) The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1: 708-16

Spracklin DK, Chen D, Bergman AJ, Callegari E, Obach SR (2020) Mini-Review:
Comprehensive Drug Disposition Knowledge Generated in the Modern Human
Radiolabeled ADME Study. CPT Pharmacometrics Syst Pharmacol 9: 428–434.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W,
Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ,
Faller DV, Savona MR (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme
inhibitor, combined with azacitidine in patients with AML. Blood 131: 1415-1424.

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ,
Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC (2015) Pevonedistat
(MLN4924), a first-in-class NEDD8-activationg enzyme inhibitor, in patients with acute
myeloid leukemia and myelodysplastic syndromes- a phase I study. Br J Hematol
169:534-43

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,
Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) Inhibition of
NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid
leukemia. Blood 115:3796-800.

Tse S, Leung L, Raje S, Seymour M, Shishikura Y, Obach SR (2014) Disposition and Metabolic
Profiling of [^{14}C]Cerlapirdine Using Accelerator Mass Spectrometry. Drug Metab Dispos
42:2023-2032.

Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz MH, Crespi CL, Greenblatt DJ (2000)
Comparison between cytochrome P450 (CYP) content and relative activity approaches to
scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory

proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493–1504.

Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326–337.

US Department of Health and Human Services. Safety Testing of Drug Metabolites Guidance for Industry. Silver Spring, MD: Center for Drug Evaluation and Research, Food and Drug Administration, 2020.

Yeo RK, Venkatakrishnan K (2021) Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study. Clin Pharmacol Ther 109:51-54.

Yoshikado T, Maeda K, Furihara S, Terashima H, Nakayama T, Yishigame K, Tsunemoto K, Kushuhara H, Furihara, K-i, Suguyama Y (2017) A clinical cassette dosing study for evaluating OATPs and CYP3A to drug-drug interactions Pharm res 34: 1570-83

Zhao A, Sun Y (2013) Cullin-RING ligases as attractive anti-cancer targets. Curr Pharm Des 19: 3215-3225.

Zhao Y, Morgan MA, Sun Y (2014) Targeting neddylation pathways to inactivate cullin-RING ligases for anticancer therapy. Antioxid Redox Signal 21: 2383-2400.

Zhou X, Sedarati F, Faller DV, Zhao D, Faessel HM, Chowdhury S, Bolleddula J, Li Y, Venkatakrishnan K, Papai Z (2021a) Phase I study assessing the mass balance, pharmacokinetics, and excretion of [^{14}C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest New Drugs 39:488-498.

Zhou X, Ke A, Burt H, Yoneyama, T, Chuang BC, Pusalkar S, Chowdhury SK, Sedarati F, Venkatakrishnan K, Gupta N (2021b) Hepatic uptake as a rate-determining step in clearance: a novel physiologically-based pharmacokinetic model for pevonedistat to explore the mechanisms underlying its lack of clinically observed drug-drug interactions when administered concurrently with CYP3A inhibitors and inducers. Poster presented at: American College of Clinical Pharmacology (ACCP) Virtual Annual Meeting; September 13–17, 2021.

Footnotes

This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly

owned subsidiary of Takeda Pharmaceutical Company Limited. All authors are current or former

employees of Takeda. Allison Berger declares stock or stock options in Takeda. All other authors

declare no competing interests. This work received no external funding.

This work was previously presented at the 22nd North American ISSX Meeting, July 15–19,

2018; Abstract P120, and as a poster at the 2021 ACCP Virtual Annual Meeting, September

17–21, 2021; Abstract 030.

Figure Legends

Figure 1. Biotransformation pathways of pevonedistat in humans.

*Position of ^{14}C-label

FE, feces; Gluc, glucuronide; PL, plasma; UR, urine.

Figure 2. Representative radio-chromatograms of A) plasma, B) urine, and C) feces after intravenous infusion of [^{14}C]pevonedistat.

CPM, counts per minute ; DPM, disintegrations per minute; Pevo, [^{14}C]pevonedistat.

Tables

Table 1. Relative distribution of metabolites in pooled plasma (% drug-related material), urine

(% dose), and feces (% dose) after intravenous administration of [^{14}C]pevonedistat

	Plasma (% Total Radioactivity)	Percent Dose		
		Urine	Feces	Total (Urine + Feces)
Pevonedistat	49.3 ± 9.8	4.3 ± 2.5	16.7 ± 7.6	21.1 ± 8.4
M1 (ML00756900)	14.6 ± 4.9	19.5 ± 2.5	7.2 ± 4.0	26.7 ± 6.7
M2 (ML00756899)	21.5 ± 3	8.1 ± 2.2	18.1 ± 3.4	26.2 ± 1.9
M3 (ML00756898)	4.5 ± 0.6	4.2 ± 0.8	10.8 ± 2.0	14.9 ± 1.5
M7	0.8 ± 0.3	0.8 ± 0.3	0.7 ± 0.2	1.5 ± 0.2
M10b	6.5 ± 2.1	1.5 ± 0.7	-	1.5 ± 0.7
M16	1 ± 0.4	2.5 ± 0.8	-	2.5 ± 0.8
M22	1.9 ± 0.8	0.7 ± 0.4	-	0.7 ± 0.4
M23	-	<1%	-	<1%

Note: Metabolite profiles were presented for n = 7; "-": Not observed. M23 is a minor unknown

metabolite.

Table 2. Pevonedistat metabolites detected and identified in plasma, urine, and feces of patients administered an intravenous dose of pevonedistat.

Pevonedistat and Metabolites	Matrix	HPLC RT (min)*	Observed [M+H]+ at m/z	Calculated [M+H]+ at m/z	Mass Error (ppm)	LC/MS/MS Key Fragment Ions	Chemical Structure
Pevonedistat	P, U, F	45.51	444.1690	444.1700	-2.3	347, 328, 231, 135, 117	Confirmed with the standard reference
M1 (ML00756900) [a]	P, U, F	31.49	460.1661	460.1649	2.6	442, 363, 345, 328, 249, 231, 135, 133, 115	Confirmed with the standard reference
M2 (ML00756899) [a]	P, U, F	39.16	458.1496	458.1493	0.7	440, 361, 328, 265, 231,135,131	Confirmed with the standard reference
M3 (ML00756898)[a]	P, U, F	29.25	460.1659	460.1649	2.2	442, 363, 345, 328, 231, 135, 133	Confirmed with the standard reference
M7	P, U, F	17.29	328.1086	328.1074	3.7	328, 249, 231, 135	Assigned by LC-HRMS
M10b	P, U	22.09	636.1984	636.1970	2.2	460, 442, 363, 345, 328, 231, 135, 115	Assigned by LC-HRMS
M16	P, U	41.44	620.2021	620.2021	0	444, 328, 231, 135, 117	Assigned by LC-HRMS
M22	P, U	23.75	636.1943	636.1970	-4.2	460, 328, 231, 135, 133	Assigned by LC-HRMS
M23	U	12.5	-	-	-	-	Unknown

F, feces; HPLC, high-performance liquid chromatography; HRMS, high-resolution mass spectrometry; LC, liquid chromatography; LC/MS/MS, liquid chromatography with tandem mass spectrometry; *m/z*, mass-to-charge ratio; P, plasma; ppm, parts per million; RT, retention time; U, urine; "-": Not available.

Note: Slight retention time shift was observed between matrices, but peaks were assigned based on mass spectral data.

[a]Standard references.

Table 3. Intrinsic clearance of pevonedistat (0.1-µM) by recombinant cytochrome P450

isozymes.

CYP Isozyme (20-pmol/mL/0.5 mg protein)	$CL_{int,rCYP}$ (mL/min/pmol P450)	RAF	% Contribution
1A2	7.44E-05	18.0	1.3
2A6	NC	-	NC
2B6	8.35E-05	15.8	1.3
2C8	1.04E-04	21.9	2.3
2C9	5.99E-05	19.0	1.1
2C19	4.34E-05	1.4	0.1
2D6	3.33E-05	8.1	0.3
2E1	NC	-	NC
3A4/5	3.27E-03	30.5	93.6
2J2	7.01E-04	-	NC
1A1	3.21E-04	-	NC

CYP, cytochrome P450; N/C, no clearance; RAF: Relative activity factor; "-": Not determined.

Table 4. Pharmacological activity of pevonedistat and its metabolites: M1, M2, and M3.

Pevonedistat and Metabolites	NAE Inhibition (IC_{50} μM)	NF-κB Inhibition (IC_{50} μM)	Cell Viability[a] (LD_{50} μM)	% Distribution in Plasma	% Contribution to Overall Pharmacology of Pevonedistat[b]
Pevonedistat	0.004	0.016	0.12	49	60.6
M1 (ML00756898)	0.004	0.13	0.41	14.6	21.2
M2 (ML00756899)	0.010	0.13	0.43	21.5	13.9
M3 (ML007568900)	0.006	0.20	0.99	4.48	4.2

IC_{50}, 50% inhibitory concentration; LD_{50}, dose causing lethality for 50% of the population; NAE, NEDD8-activating enzyme; NF-κB, nuclear factor-kappa B.

[a]As measured in HCT116 cells.

[b]Calculated as percent circulating $\times 1/IC_{50}$ * fu (measured by NF-κB inhibition, the most relevant assay for pharmacodynamics because it takes cellular permeability into account and represents a mechanism of action (MOA)-relevant pathway inhibition).

Note: fractions unbound (fu) in plasma for pevonedistat, M1, M2, and M3 are 3%, 28.7%, 12.7%, 28.7%, respectively.

Table 5. Exposure of M1 and M2 in rat, dog, and human plasma.

	M1			M2		
	Human	**Dog**	**Rat**	**Human**	**Dog**	**Rat**
$AUC_t{}^{a}$	576	2376	633	792	4392	1463
Exposure ratio[b]	NA	4.1	1.1	NA	5.5	1.8

[a]AUC_t derived from metabolite profiling of AUC-pooled plasma samples to contain >4 $t_{1/2}$.

[b]Animal/human exposure ratio. Rats and dogs were dosed with [^{14}C]pevonedistat IV at 30 and 15 mg/kg, respectively; humans were dosed with [^{14}C]pevonedistat IV at 25 mg/m^2.

AUC_t, area under the plasma concentration time curve; IV, intravenous; $t_{1/2}$, half-life; NA: Not applicable.

Figure 1

Figure 2

A)

B)

C)